Cetinkaya, N. | Attar, Rukset | Yildirim, G. | Ficicioglu, C. | Ozkan, F. | Yılmaz, B. | Yesildaglar, N.

Article | 2015 | Archives of Gynecology and Obstetrics291 ( 3 ) , pp.591 - 598

Aims: To determine the effects of different doses of melatonin treatment on endometrial implants, the activity of antioxidant enzyme superoxide dismutase (SOD), the angiogenesis factor, the vascular endothelial growth factor (VEGF) and the waste metabolite product of lipid peroxidation malondialdehyde (MDA) in an oophorectomized rat endometriosis model.Methods: Thirty-two, female, non-pregnant, nulligravid Sprague–Dawley, albino rats were used in this prospective, randomized, controlled and experimental study. Endometriosis was surgically induced in oophorectomized rats, and estradiol treatment was started after the first operation . . .and continued till the end of the study. Second look, third look and necropsy operations were performed in the 2nd, 4th and 6th weeks. Mean volumes, histological scores and biochemical parameters were evaluated throughout the study.Results: The mean volumes of endometriotic foci were 98.8 mm3 ± 17.2 vs. 108.2 mm3 ± 17.5, 54.1 mm3 ± 15.6 vs. 25.8 mm3 ± 3.6, 42.8 mm3 ± 10.5 vs. 32.7 mm3 ± 6.0 and histopathological scores were 2.2 ± 0.2 vs. 1.7 ± 0.1, 2.6 ± 0.2 vs. 2.2 ± 0.2, 2.6 ± 0.1 vs. 2.7 ± 0.2 in the 10 vs. 20-mg/kg/day melatonin group at the end of the second, fourth and sixth weeks, respectively. When the groups were compared, no significant differences were seen in the histopathologic scores, SOD and VEGF levels between the groups. However, the endometriotic foci volumes were significantly decreased in both melatonin treatment groups with respect to the control group at the end of the fourth and sixth weeks. Moreover, the mean MDA levels were significantly lower in the control group than in the 10-mg/kg/day melatonin group at the end of the fourth and sixth weeks.Conclusion: Melatonin treatment resulted in the regression of endometriotic lesions in oophorectomized rats. Higher doses of melatonin treatment might be more effective in the regression of implants and improvement of histologic scores as well as in the precise evaluation of SOD, MDA and VEGF distributions in the rat experimental models. © 2014, Springer-Verlag Berlin Heidelberg Daha fazlası Daha az

Attar, Rukset | Yildirim, G. | Kumbak, B. | Ficicioglu, C. | Demirbag, S. | Yesildaglar, N.

Article | 2011 | Journal of Obstetrics and Gynaecology Research37 ( 2 ) , pp.125 - 131

Aim: To evaluate the efficacy of hyaluronate/carboxymethylcellulose (HA/CMC) membrane and melatonin separately and in combination in reducing adhesion reformation following adhesiolysis of surgically induced adhesions in a rat uterine horn adhesion model. Methods: A randomized, prospective study was carried out in a university animal laboratory. Ninety-eight female Sprague-Dawley albino rats were operated on. Following infliction of standard lesions, all the animals underwent second operations after one week. In all the animals, there were dense and vascular adhesions only between the uterine horns. These adhesions were lysed. Follo . . .wing the completion of adhesiolysis, the animals were randomized before closure of the abdomen to one of four groups (melatonin, HA/CMC membrane, combination of melatonin and HA/CMC membrane, control group). Seven days after the second surgery, the third operations were carried out and adhesions were scored. The main outcome measures were type, tenacity, and extent of adhesions. Total adhesion scores were determined. Results: Adhesion scores in the melatonin and HA/CMC membrane groups were similar, and significantly lower than those in the control group (P < 0.001). Adhesion scores in the combination group were lower than those in the other three groups (P < 0.001). Conclusion: Melatonin and HA/CMC membrane are both effective separately in preventing adhesion reformation following adhesiolysis, but in combination they are signiicantly more beneicial. © 2010 Japan Society of Obstetrics and Gynecology Daha fazlası Daha az

Farooqi, A.A. | Jabeen, S. | Attar, Rukset | Yaylim, I. | Xu, B.

Review | 2018 | Journal of Cellular Biochemistry119 ( 12 ) , pp.9664 - 9674

Recent technological and analytical breakthroughs in genomics and proteomics have deepened our understanding related to the multifaceted nature of cancer. Because of therapeutically challenging nature of cancer, there has been a renewed interest in phytochemistry, and much attention is currently being given to the identification of signaling pathway inhibitors. Data obtained through high-throughput technologies has provided a broader landscape of wiring maps of complex oncogenic signaling networks, thus revealing novel therapeutic opportunities. Increasingly, it is being realized that although our knowledge related to physiological . . .and pathophysiological roles of signal transduction cascades has evolved rapidly, the clinical development of signaling pathway inhibitors has been challenging. Quercetin has attracted considerable attention because of its amazingly high pharmacological value. Research over decades has sequentially shown that quercetin effectively inhibited cancer development and progression. In this review, we have attempted to set the spotlight on the regulation of different cell signaling pathways by quercetin. We partition this multicomponent review into how quercetin effectively regulates the Wnt/ß-catenin pathway, Janus kinase-signal transducer and activator of transcription pathway, and vascular endothelial growth factor/vascular endothelial growth factor receptor signaling cascade in different types of cancers. We also provide an overview of the regulation of NOTCH and SHH pathways by quercetin. MicroRNAs (miRNAs) have also emerged as versatile regulators of cancer, and contemporary studies have shed light on the ability of quercetin to control different miRNAs in various cancers. We have scattered information related to NOTCH and SHH pathways, and future studies must converge on the investigation of these pathways to see how quercetin modulates the signaling machinery of these pathways. © 2018 Wiley Periodicals, Inc Daha fazlası Daha az

Farooqi, A.A. | Khalid, S. | Tahir, F. | Sabitaliyevich, U.Y. | Yaylim, I. | Attar, Rukset | Xu, B.

Article | 2018 | Food and Chemical Toxicology119 , pp.98 - 105

Research over decades has progressively explored pharmacological actions of bitter gourd (Momordica charantia). Biologically and pharmacologically active molecules isolated from M. charantia have shown significant anti-cancer activity in cancer cell lines and xenografted mice. In this review spotlight was set on the bioactive compounds isolated from M. charantia that effectively inhibited cancer development and progression via regulation of protein network in cancer cells. We summarize most recent high-quality research work in cancer cell lines and xenografted mice related to tumor suppressive role-play of M. charantia and its bioac . . .tive compounds. Although M. charantia mediated health promoting, anti-diabetic, hepatoprotective, anti-inflammatory effects have been extensively investigated, there is insufficient information related to regulation of signaling networks by bioactive molecules obtained from M. charantia in different cancers. M. charantia has been shown to modulate AKT/mTOR/p70S6K signaling, p38MAPK-MAPKAPK-2/HSP-27 pathway, cell cycle regulatory proteins and apoptosis-associated proteins in different cancers. However, still there are visible knowledge gaps related to the drug targets in different cancers because we have not yet developed comprehensive understanding of the M. charantia mediated regulation of signal transduction pathways. To explore these questions, experimental platforms are needed that can prove to be helpful in getting a step closer to personalized medicine. © 2018 Elsevier Lt Daha fazlası Daha az

Ficicioglu, C. | Kumbak, B. | Akcin, O. | Attar, Rukset | Yildirim, G. | Yesildaglar, N.

Article | 2010 | Gynecological Endocrinology26 ( 3 ) , pp.181 - 186

Background. This study investigated whether follicular fluid (FF) and serum (S) concentrations of cytokines in women undergoing assisted reproductive treatment (ART) were different in GnRH antagonist cycles compared to agonist long ones. Methods. A retrospective clinical study was performed at a University ART center. A total of 85 women who underwent ART either with agonist long (n=34) or antagonist protocol (n=51) were analyzed. FF and serum samples were collected at the time of oocyte retrieval and measured for interleukin (IL)- 1ß, IL-6, IL-8, IL-12, tumor necrosis factor (TNF)-? by the enzyme-linked immunosorbent assay (ELISA) . . .technique, using commercially available kits and nitric oxide (NO) by the nitrate/nitrite colorimetric assay. The results were compared between GnRH antagonist and agonist cycles. Results. No significant difference was found in the FF concentrations of those cytokines between the two protocols. The serum values were also similar in the two groups except IL-6 (14.3±4.8 vs. 20.5±12.2 pg/ml; p=0.008) and NO (1.4±1.1 vs. 2.2±1.9 µm; p=0.038) levels which were found to be significantly lower in antagonist cycles. Conclusions. There is no significant difference in follicular microenvironment in terms of IL-1ß, IL-6, IL-8, IL-12, TNF-?, and NO levels between agonist long and antagonist cycles. However, serum IL-6 and NO levels were lower in women given antagonists. © 2010 Informa UK Ltd Daha fazlası Daha az